Any manufacturing industry's digitization is a vital step in the evolution of the manufacturing process. Increased usage of robots, automation solutions, and computerization are all part of the digitalization process, which results in cost savings, increased efficiency and production, and more adaptability to change. However, the pharmaceutical industry (PI) has been resistive to digitization, owing to a lack of experience and the complexity of the development and manufacturing procedures involved. Despite this, there is a definite need to digitalize PI, as demand for both traditional and novel pharmaceuticals continues to rise. CDMOs (Contract Development Manufacturing Organizations) have a unique digitalization problem. The primary features of Good Manufacturing Practice (GMP) should be closely linked to PI digitalization, and CDMO in particular, and success in PI digitalization necessitates a consistent focus on GMP. Another key thing to consider during CDMO digitalization is close communication with continually changing stakeholders. This article provides an overview of the key components of CDMO digitization and covers both the benefits and drawbacks of the process, with a focus on practical solutions for further digital implementation.
Author(S) Details
Glenn Hole
Molde University College, Molde and Procuratio Consulting, Drammen, Norway.
Anastasia S. Hole
Helseviten AS, Drammen, Norway.
Ian McFalone-Shaw
Molde University College, Molde and Procuratio Consulting, Drammen, Norway.
View Book:- https://stm.bookpi.org/IST-V5/article/view/5708
No comments:
Post a Comment